On June 6, 2018 Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSXV:APC) (FSE:0E8) is pleased to reported the appointment of Mr. Bill Dickie as Chief Executive Officer, President and Director of the company, effective June 6, 2018 (Press release, Advanced Proteome Therapeutics, JUN 6, 2018, View Source [SID1234527225]). Mr. Dickie brings with him more than 30 years of exceptionally qualified experience in business leadership, development and execution of growth strategies within the healthcare and pharmaceutical sectors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Dickie joins APC after serving as Co-founder, President, CEO and Director of Atreus Pharmaceuticals, a radiopharmaceutical development company in Phase II clinical trials with a medical imaging product licensed from Stanford University. Under Bill’s leadership, Atreus raised $1 million in seed capital and negotiated a $6 million strategic investment, followed by a full acquisition by Advanced Accelerator Applications International, currently a Novartis company.

Previously Bill served as President, CEO and Director of Liponex Inc., (TSX:LPX) a Phase 2 company developing a novel cardiovascular drug based on technology licensed from the University of Ottawa Heart Institute. During his time as CEO, Liponex raised $10.5 Million in an IPO. Bill also spent over 25 years in management and executive roles with MDS Nordion, a large Canadian health care company. Bill’s extensive experience provides Advanced Proteome with the necessary guidance, leadership and expertise during this next, important phase of its development.

"We are delighted to welcome Bill to the Advanced Proteome team and are extremely fortunate to have his services," said Dr. Allen Krantz, founder and Chief Scientific Officer of Advanced Proteome Therapeutics. "We are confident that his keen intelligence, high standards, and strong work ethic along with his experience in leadership roles within the healthcare sector qualify him to enable our universal linker technology to realize its full potential. We look forward to his leadership and will consolidate our operations around his vision."

"I am honored to join the Advanced Proteome Therapeutics team and help lead the efforts to develop this proprietary and groundbreaking linker technology that will create superior versions of antibody-drug conjugates in the fight against cancer," said Bill Dickie, CEO and President of Advanced Proteome Therapeutics. "This proprietary approach has tremendous value and potential. I am confident we will implement a strategy for APC based on joint ventures, collaborations and licensing agreements with leading pharmaceutical companies which will bring significant value to the company and its shareholders."

On June 6, 2018 Peloton Therapeutics, Inc., reported dosing of the first patient in a Phase 2 trial evaluating the efficacy and safety of lead investigational oncology agent , PT2977, to treat von Hippel-Lindau (VHL) disease-associated kidney cancer (Press release, Peloton Therapeutics, JUN 6, 2018, View Source [SID1234527212]). PT2977 is a once-daily, oral inhibitor of HIF-2α, a transcription factor that has been implicated in the development and progression of renal cell carcinoma (RCC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The initiation of this Phase 2 trial is an important milestone for Peloton and a critical step towards helping patients with this rare condition which can have serious lifelong health consequences," said Mohammad Hirmand, M.D., Peloton’s Chief Medical Officer. "The safety, pharmacokinetics, and clinical activity that we have observed in a Phase 1 trial of PT2977 provides insights into its potential to improve outcomes for patients with kidney cancer. We look forward to continuing clinical evaluation of this novel oral HIF-2α inhibitor."

The primary objective of the Phase 2 trial is to evaluate the efficacy of PT2977 for the treatment of VHL disease-associated renal tumors as measured by overall response rate. Secondary objectives include duration of response, time to response, progression free survival, and time to surgery for VHL disease-associated renal tumors. The trial will also evaluate the efficacy of PT2977 in other VHL disease-associated tumor types as well as the safety and pharmacokinetics of PT2977. Patients will be evaluated radiologically approximately every 12 weeks while continuing in the study.

"Unfortunately, there are no approved systemic therapies available for VHL disease. Currently, the only option is surgery, sometimes required multiple times which can be devastating for patients and does not cure the disease," said Eric Jonasch, M.D., Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine; Director, VHL Clinical Center, The University of Texas MD Anderson Cancer Center. "We are excited about the opportunity to study PT2977 which may offer a new option as an orally available agent that could reduce the need and frequency of surgical intervention for patients with VHL-associated kidney disease."

Peloton’s drug discovery and development efforts focus on identifying novel compounds capable of modulating complex protein-protein interactions that drive disease which have eluded conventional small molecule approaches. Peloton has the only clinical stage small-molecule inhibitors of HIF-2α, and PT2977 has demonstrated a favorable profile in a Phase 1 study in patients with advanced solid tumors including RCC.

The study will enroll 50 patients at clinical trial centers across the United States and Europe. More information about the trial is available at www.clinicaltrials.gov, identifier NCT NCT03401788.

About VHL Disease

Von Hippel-Lindau (VHL) disease is a rare, hereditary cancer syndrome in which affected individuals have a mutation and/or deletion of the tumor suppressor VHL gene, and are at risk for the development of multiple tumors including renal cell cancer. The global incidence of VHL is estimated to be one in 36,000 people.

About PT2977

Peloton has succeeded in creating a series of orally-available small molecules that bind to HIF-2α and inhibit its transcription of disease-promoting genes. PT2977 is a once-daily, orally-active agent that blocks hypoxia-inducible factor-2α (HIF-2α). It is a structurally-related compound designed to be more potent with less pharmacokinetics variability compared to PT2385. PT2977 has demonstrated anti-tumor activity with a favorable safety profile in an early-stage clinical study in patients with solid tumors. Given its superior profile, PT2977 is the lead agent being developed in oncology by Peloton. In addition to the international Phase 2 trial of PT2977 in VHL disease-associated RCC, Peloton is evaluating the agent in a Phase 1 clinical trial for the treatment of advanced RCC.

On June 6, 2018 Rubius Therapeutics, a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, reported the appointment of Pablo J. Cagnoni, M.D., as Chief Executive Officer (Press release, Rubius Therapeutics, JUN 6, 2018, View Source [SID1234527211]). Torben Straight Nissen, Rubius’ President, will partner with Dr. Cagnoni to continue to advance the company’s pipeline and other business objectives.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Pablo’s deep industry expertise and role in the development and commercialization of more than 20 life-changing treatments positions him to lead Rubius as we continue to advance a new class of medicines to treat cancer, autoimmune diseases and rare diseases," said David Epstein, Chairman of Rubius Therapeutics. "We are extremely pleased to welcome Pablo as CEO."

Over the course of Dr. Cagnoni’s career as an oncologist and pharmaceutical executive, he has played a key role in the development, approval and commercialization of several transformative medicines, including Afinitor, Kyprolis and Tarceva. He most recently served as President and Chief Executive Officer of Tizona Therapeutics, a privately held biotech company focused on developing novel treatments for cancer. Prior to Tizona, Dr. Cagnoni served as President of Onyx Pharmaceuticals, Global Head of Clinical Development at Novartis Oncology, and Chief Medical Officer at Allos Therapeutics and OSI Pharmaceuticals, respectively. Dr. Cagnoni received his M.D. from the University of Buenos Aires School of Medicine, and completed fellowships in Hematology and Oncology at the Mount Sinai Medical Center, and in Stem Cell Transplantation at the University of Colorado Health Sciences Center.

"I am honored to join Rubius as CEO to continue building the company’s broad and diverse pipeline of Red Cell Therapeutics in multiple therapeutic areas, while making a significant impact for patients with serious diseases," said Dr. Cagnoni. "I look forward to partnering with Torben and the entire team

On June 6, 2018 Protagonist Therapeutics, Inc. (Nasdaq:PTGX) reported that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 2018 JMP Securities Life Sciences Conference taking place June 20-21 at the St. Regis Hotel in New York, NY (Press release, Protagonist, JUN 6, 2018, View Source;p=RssLanding&cat=news&id=2353461 [SID1234527210]). The Protagonist Therapeutics presentation is scheduled for Wednesday, June 20, at 2 p.m. EDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live and archived webcast of the presentation can be accessed by visiting the Investors page of the Protagonist Therapeutics corporate website at View Source

On June 6, 2018 Pieris Pharmaceuticals, Inc. presented the Jefferies Global Healthcare Conference presentation of Pieris Pharmaceuticals, Inc (Presentation, Pieris Pharmaceuticals, JUN 6, 2018, View Source [SID1234527206]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!